Meeting NewsVideo

VIDEO: Timely biomarker work-up helps ensure optimal lung cancer treatment

NEW YORK — This year’s HemOnc Today New York meeting kicked off with a session dedicated to treatment advances and challenges in lung cancer.

Precision medicine approaches have dramatically altered treatment approaches and improved outcomes for patients, according to program co-chair Edward S. Kim, MD, FACP, chair of solid tumor oncology and investigational therapeutics at Levine Cancer Institute at Atrium Health.

Kim and other presenters in the lung cancer session discussed the value of biomarkers and driver mutations. They also emphasized the importance of early work-up to inform appropriate treatment decisions.

“We need the right markers done in a timely manner so medical oncologists and other professionals can ... apply [this information] to their patients to deliver the very best care,” Kim told HemOnc Today.

 

Disclosure: Kim reports consultant roles with AstraZeneca, Boehringer Ingelheim, Merck and Takeda; research funding from AstraZeneca, Boehringer Ingelheim, Ignyta and Merck; and a data and safety monitoring board role with Celltrion.

NEW YORK — This year’s HemOnc Today New York meeting kicked off with a session dedicated to treatment advances and challenges in lung cancer.

Precision medicine approaches have dramatically altered treatment approaches and improved outcomes for patients, according to program co-chair Edward S. Kim, MD, FACP, chair of solid tumor oncology and investigational therapeutics at Levine Cancer Institute at Atrium Health.

Kim and other presenters in the lung cancer session discussed the value of biomarkers and driver mutations. They also emphasized the importance of early work-up to inform appropriate treatment decisions.

“We need the right markers done in a timely manner so medical oncologists and other professionals can ... apply [this information] to their patients to deliver the very best care,” Kim told HemOnc Today.

 

Disclosure: Kim reports consultant roles with AstraZeneca, Boehringer Ingelheim, Merck and Takeda; research funding from AstraZeneca, Boehringer Ingelheim, Ignyta and Merck; and a data and safety monitoring board role with Celltrion.

    See more from HemOnc Today New York